Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a developer of advanced vision restoration technologies, announced that debentureholders have converted $1.4 million of their principal into common shares of the Company at a price of $0.32 per share, resulting in the issuance of 4,375,000 common shares. The conversion represents 35% of the Company’s previously outstanding debenture principal of $4 million.
This strategic move significantly strengthens Ocumetics’ balance sheet as the company advances toward key milestones in its ongoing patient study program. By converting debt to equity, Ocumetics reduces its outstanding debenture principal by 35%, which is expected to improve financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of the company’s technology platform and clinical development objectives.
“These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision,” said Dean Burns, President and CEO of Ocumetics. “We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company.”
The company is currently in the first-in-human early feasibility study phase of its game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses, and without perceptible time lag.
Ocumetics continues to advance toward key regulatory milestones, including preparation for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration. The debt conversion comes at a critical time as the company focuses on achieving the next major milestones in its patient study program.
The conversion of $1.4 million in debenture principal into common shares is expected to provide the company with a stronger financial foundation to support its research and development activities. This move reduces the company’s debt burden and interest obligations, potentially freeing up capital for clinical trials and other operational needs.
For the reader, this news signals that Ocumetics is taking proactive steps to strengthen its financial position, which could accelerate the development of its vision restoration technology. If successful, the dynamic intraocular lens could revolutionize the treatment of cataracts and presbyopia, offering patients a potential alternative to glasses or contact lenses.
The technology’s ability to mimic natural eye focusing could have significant implications for the ophthalmic industry, potentially disrupting the market for corrective lenses and intraocular implants. The company’s progress toward FDA submission further underscores the potential impact of this innovation on patient care and quality of life.
